Bayer shares soar as company records strong cancer drug demand
Bayer’s strong first quarter performance was mainly driven by its pharmaceuticals division, even as its crop-science branch lagged.
Bayer’s strong first quarter performance was mainly driven by its pharmaceuticals division, even as its crop-science branch lagged.
What's Your Reaction?
